Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a triple therapy stop strokes from coming back?

NCT ID NCT06757764

Disease control Sponsor: Asan Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding the drug cilostazol to the usual two blood thinners (aspirin and clopidogrel) can better prevent early stroke recurrence in people who had a stroke caused by narrowed arteries in the brain or neck. About 2,340 adults will be enrolled within 72 hours of their stroke. The goal is to see if the triple therapy reduces neurological worsening during hospitalization and new strokes over the next 6 months.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 2,340 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age of 20 years or older 2. Acute ischemic stroke due to large artery atherosclerosis (both including Intra and extracranial atherosclerosis) which may be defined by a ischemic lesion confirmed at diffusion-weighted image and a corresponding significant stenosis (more than 50% of diameter reduction) proximal to the ischemic lesion confirmed by MR angiography or CT angiography. 3. Informed consent obtained within 72h from stroke onset 4. Acquisition of written informed consent prior to study entry Exclusion Criteria: 1. Large infarction unable to start antiplatelet treatment 2. Combined with acute intracranial haemorrhage 3. With initial haemorrhagic transformation 4. Previous mRS higher than 2 5. Indicated for anticoagulation 6. Contraindication for aspirin, clopidogrel or cilostazol 7. Requirement of long term NSAID 8. Pre-planned for surgery 9. Unable to withdraw consent 10. Unavailable to participate based on judgement of the investigator 11. Participants of reproductive potential (PORP)/ Participants of childbearing potential (POCBP) who do not agree to practice methods of birth control or remain fully abstinent from sexual activity with the potential for conception.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute ischemic stroke due to large artery atherosclerosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cerebral infarction large artery stroke

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cerebral infarction Stenosis artery

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    24 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Asan Medical Center

    RECRUITING

    Seoul, Songpa-gu, 05505, South Korea

  • Chonnam National University Hospital

    RECRUITING

    Gwangju, South Korea

  • Chungbuk National University Hospital

    RECRUITING

    Cheongju-si, South Korea

  • Chungnam National University Hospital

    RECRUITING

    Daejeon, South Korea

  • Eulji University Hospital

    RECRUITING

    Daejeon, South Korea

  • Ewha Womans University Seoul Hospital

    RECRUITING

    Seoul, South Korea

  • Gachon University Gil Medical Center

    RECRUITING

    Incheon, 21565, South Korea

  • Hallym University Medical Center

    RECRUITING

    Gyeonggi-do, South Korea

  • Hanyang University Guri Hospital

    RECRUITING

    Gyeonggi-do, South Korea

  • Hanyang University Seoul Hospital

    RECRUITING

    Seoul, South Korea

  • Inha University Hospital

    RECRUITING

    Incheon, South Korea

  • Jeju National University Hospital

    RECRUITING

    Jeju City, South Korea

  • Jeonbuk National University Hospital

    RECRUITING

    Jeonju, South Korea

  • Korea University Ansan Hospital

    RECRUITING

    Gyeonggi-do, South Korea

  • Korea University Guro Hospital

    RECRUITING

    Seoul, South Korea

  • Kyung Hee University Hospital

    RECRUITING

    Seoul, South Korea

  • Kyung Hee University Hospital at Gangdong

    RECRUITING

    Seoul, South Korea

  • Kyungpook National University Chilgok Hospital

    RECRUITING

    Daegu, South Korea

  • Pusan National University Hospital

    RECRUITING

    Busan, South Korea

  • Pusan National University Yangsan Hospital

    RECRUITING

    Yangsan, South Korea

  • Samsung Medical Center

    RECRUITING

    Seoul, South Korea

  • Seoul National University Bundang Hospital

    RECRUITING

    Gyeonggi-do, 13620, South Korea

  • The Catholic University of Korea, Seoul St. Mary's Hospital

    RECRUITING

    Seoul, South Korea

  • Yonsei University Health System, Gangnam Severance Hospital

    NOT_YET_RECRUITING

    Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.